2 super US BIO Werte: MYRIAD Genetics & IDEC-Pharmaceuticals - 500 Beiträge pro Seite

[chartmike]

Hallo,
hier noch zwei echt gute Bio Werte die ich in die reihe wie Medarex oder Protein Disingn stelle.
Vom langfrist Chart sind beide genau wie die meisten Bios seit dem Tief anfang Juni ca. 80% gelaufen.
Beide haben noch Potential und bringen super meldungen raus.
MYRIAD Genetics WKN 897518 US kürzel MYGN
und
IDEC Parmaceuticals WKN 883218 US kürzel IDEC

Schaut euch mal die Charts bei www.SILICONINVESTOR.com an.
Beide sind keine Penny Stocks!!
Es gibt wenige Beiträge hier im Board aber die Werte sind Top.
Bei einer weiter anhaltenden Bio Welle sind beide vorne dabei.
Ich würde gern euch die Charts Posten aber es funktioniert nicht.
Hat einer ein Tip wie das geht.

Chartmike

[chartmike]

Hallo hier habe ich den Link zum Chart.http://www.siliconinvestor.com/research/chart.gsp?lotemp=&pe…
Chartmike

[IWA Japan]

vielleicht wird darüber nicht viel geschrieben, wenn dan aber was sinnvolles, siehe IDPH von mir und MYGN von mlynched!


P.S: Kannst du keine cHarts liefern?

[mahatma]

hier noch die Seite mit den " Strong Buy " und guten News
http://quicken.excite.com/investments/estimates/?symbol=MYgn
(so nebenbei , ist meine Lieblingsaktie , aber leider nur ein kleiner Posten in meinem Depot / schade,schaaaaaadddeeee)


maha

[mahatma]

mygn steht heute wieder gut im Futter !!!!!!!!!!!!!!!!!!!!!!!!!!1


maha

[mahatma]

Myriad Genetics ist ein in Salt Lake City/ USA ansässiges
Biotechnologieunternehmen, das Produkte zur Therapie und zur frühzeitigen
Diagnose von krebsartigen Geschwüren, Infektionen und Entzündungen erforscht
und entwickelt.

Myriad ist ein interessantes Unternehmen mit enormen
Zukunftschancen. Aufgrund der hervorragenden Position im Bereich der
Genanalyse bei Verdacht auf Mutationen ist auch der bereits hoch erscheinende
Kurs gerechtfertigt. Der Biotechnologiesektor, und speziell der Krebssektor
werden in den nächsten Jahren einen enormen Umsatzsprung machen. Doch
Leiden können nur effektiv bekämpft werden, wenn sie rechtzeitig oder besser
noch vor dem Ausbruch durch geeignete Tests diagnostiziert werden. Hier nimmt
Myriad zur Zeit noch eine Schlüsselrolle ein, welche die Aktie in unseren Augen
sehr attraktiv macht. Jedoch sollten Investoren Zeit mitbringen, denn das
Unternehmen wird voraussichtlich erst 2004 den break-even schaffen, erste
Produkte aus der Pipeline lassen wahrscheinlich auch noch einige Zeit auf sich
warten.
Das ganz unter http://www.trading-division.de/Version2/Seiten/biotech.html

gruß maha

[mahatma]

heute ohne Kommentar

gruß maha

[mahatma]

oh man oh man,
das geht ja heute wieder abbbbbbbbbbbbbbbbbbbbbbbbbbbb !!!!!!!!!!!!!!!!!!!

Wahhhhhhhhhhhnnnnnnnnnnnnnnsiiiiiiiiiiinnnnnnnnnnnnn
grüße an alle Inder und Afrikaner
maha

[mahatma]

Fakten, Fakten, Fakten:
Prudential bewertet Biotechunternehmen

Das Analystenhaus Prudential hat heute ohne weiteren
Kommentar eine erstmalige Einstufung einer Reihe von
Biotechnologieunternehmen vorgenommen:

Myriad Genetic
(Nasdaq: MYGN) als „Strong Buy“

gruß maha

[Clark-W.Griswaldt]

heute?

[mahatma]

MYRIAD GENETICS INITIATED WITH `STRONG BUY/SINGLE BEST IDEA` AT PRUDENTIAL - CBS
MarketWatch.com
s.a. http://www2.marketwatch.com/news/search.asp?SearchOption=tic…
gruß maha

[mahatma]

super,super muß mich einfach wieder einmal melden !!!!!!!!!!!!!!!!!!!


heute gehts wieder mächtig ab!!!!!!!!!
grüße alle , maha

[mahatma]

das hammr uns verdient , das hammr uns verdient ; der Song ist geil - gell ?!
und MYRIAD auch !!!!!!!!!!!!!!!!!!!!
Hiermit Grüße ich die PRUDENTIAL - BOYS , weiter so Ihr seit euer Geld wert !!!!!!


maha

[Klostolani]

Geduld zahlt sich eben doch aus.Bei 17,40€ Myriad gekauft,und nicht mehr lange,dann sind
sie auch noch Steuerfrei

[mahatma]

der heutige Tag:


s.a. unter :http://iw.thomsoninvest.net/iwatch/cgi-bin/iw_page
MYGN ist und bleibt ein TOP-TIP
maha

[mahatma]

leute schaut euch die indikatoren an !!!! (es geht wieder bergauf)
super news http://biz.yahoo.com/n/m/mygn.html
super kurs !!! zum einsteigen ??!!??!!

was will man mehr
MYGN gogogogogo
maha

[mahatma]

maha

[mahatma]

WWWaaaaaaaaaaaahhhhhhhhhhhhhhhhhhhhhhhhhhhnnnnnnnnnnnnnnnnnnnnnnnnnnsssiin
Myriad geht heute wieder aaaaaaaaaaab b b b !!!!!!!!!!!!!!



ich grüße heute Cape Town (besonders Rene sowie Marius von Bukarest !!)

gruß maha

[mahatma]

Myriad Genetics erneut `Strong Buy`
und das sind die Jungs und Mädls die dafür verantwortlich sind !!!!!!!!!!!

Analyst Firms Making Recommendations:
CIBC WORLD MARKETS CORP.
DAIN RAUSCHER WESSELS
JOSEPHTHAL & COMPANY
MORGAN STANLEY, DEAN WITTER DISCOVER
OSCAR GRUSS & SON
PRUDENTIAL VECTOR HEALTH CARE GROUP / im besonderen M.Geller - Goldjunge !!!!
THOMAS WEISEL PARTNERS

hier noch für alle die entsprechende Nachricht von heute: http://www.nasdaq.com/asp/quotes_news.asp?selected=mygn&sour…

gruß maha

[WMFM]

Myriad Genetics Introduces ProSpec(TM) - New Generation Mass Spectrometry/Proteomics Technology- ProSpec and ProNet Coupled to Enhance Myriad Drug Discovery Programs -
SALT LAKE CITY, Oct 17, 2000 /PRNewswire via COMTEX/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has introduced ProSpec(TM), a powerful new drug target identification and validation technology. This new proteomics technology complements the disease pathway discovery capability of Myriad`s ProNet(TM) technologies with the use of mass spectrometry to identify protein complexes. Complexes of interacting proteins are required for virtually all biological processes in the cell. The unique combination of Myriad`s ProNet version of yeast two-hybrid and mass spectrometry technologies creates an unparalleled tool for drug discovery and development.

As a leader in proteomics, Myriad introduced ProSpec to better understand how proteins function in human disease. ProSpec complements Myriad`s ProNet technology by enabling detection of extracellular protein interactions and protein complexes containing proteins that require modification for the interactions to occur. In addition, ProSpec uses the mass spectrometer to deliver structural information about three dimensional protein complexes. This information, coupled with ProNet data, may lead to considerable acceleration in the discovery of novel drug targets for both treatment and prevention of human disease.

"ProSpec is a giant leap forward in creating real value for drug developers out of information from the human genome," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "Myriad`s internal drug discovery programs and those of our pharmaceutical partners will both employ high-throughput protein interaction technology and mass spectrometry for three dimensional protein complexes to identify important disease pathways and promising drug targets in those pathways."

No other proteomics company, to the Company`s knowledge, has introduced an integrated pathway discovery technology that incorporates both yeast two-hybrid and mass spectrometry tools. The ProSpec technology is particularly amenable to large-scale protein identification projects.

Only 5% of the human genome has an obviously important function. This 5% of the DNA is the portion that codes for proteins. First generation proteomics technologies provided basic protein information such as the sequence of the protein and the relative quantity of the proteins in disease tissues. Protein interaction technologies, such as Myriad`s ProNet, are a major advancement in that they provide an understanding of the complete disease pathway and the cellular processes that result in disease. ProNet identifies key regulators and potential drug targets in the disease pathway. These disease pathway proteins form three-dimensional complexes in which portions of proteins may be buried in the complex and unavailable for binding. ProSpec builds upon pathway identification by identifying the entire set of proteins that form multiprotein complexes. The knowledge of these proteins and the complexes they form is highly valuable for determining the druggability of a protein. Druggable targets are those that can be addressed with vaccines, small molecules, therapeutic antibodies or protein therapy approaches.

ProSpec not only identifies the set of proteins that make up a multiprotein complex, it is also effective in identifying protein interactions that require post-translational modification. For example, certain proteins require methylation or phosphorylation by enzymes before they can perform their functional role in the cell. These interactions can be detected with ProSpec although they are often invisible to other detection methods. ProSpec is highly sensitive and is amenable to very high throughput. One of the most appealing characteristics of the ProSpec technology is that it identifies protein interactions as they occur in vivo, in the natural state inside the human cell.

About Proteomics

Myriad firmly believes that proteomics will revolutionize medicine. Prior to the genomic age, all drug discovery efforts worldwide, at all pharmaceutical companies combined, developed drugs targeting only approximately 500 different proteins. These 500 drug targets are mostly from the same few overused classes of proteins. These targets are insufficient to maintain the industry`s rate of growth while building the entire future of medicine. Despite spending billions of dollars annually screening hundreds of thousands of compounds against these targets, only a very small number of new drugs are introduced commercially. To add to the difficulty, these compounds only treat the symptoms of disease, leaving the root cause of the problem unaffected.

In contrast, it is commonly believed that proteomics will produce thousands of new drug targets over the next several years. The sequencing of the human genome has accelerated the drug target discovery process to the point that the challenge is identifying the most promising, druggable targets from among the large number of possibilities. A good strong druggable target requires knowledge of the disease pathway, protein function, structure and availability.

Proteomics answers the challenge. Proteins interact with one another and form complexes to carry out essentially all human biological processes. To discover the chain of events that result in a disease state, drug developers must identify the disease pathway and the proteins involved in that pathway. Proteomics delivers this information precisely and efficiently. Proteomics- derived medicines, based on the cause of disease, not the symptoms, should be more effective with reduced side effects. These new safer drugs are also more likely to produce successful clinical trials in a reduced timeframe.

Myriad`s ProNet technology has already delivered disease pathways and protein function information and will continue to do for the Company`s global proteomics partners. The even more potent and rapid combination of ProSpec and ProNet will further the knowledge proteomics delivers by adding structure and availability, enhancing the odds of making the optimum choice of drug target for faster development of better, safer and more effective medicines.

Myriad, furthering its leadership position in proteomics, will also use ProSpec in strategic alliances to assist major pharmaceutical companies in the identification of the most promising set of druggable targets to fill their pipelines for the next generation of medicines. Proteomic technology advances such as these enable the projected industry growth from $300 billion today to the third-party projected $3 trillion by 2020.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel therapeutic products derived from its proprietary genomic and proteomic technologies. The Company has established two wholly owned subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market therapeutic compounds, and Myriad Genetic Laboratories, Inc. develops and markets proprietary predictive medicine and personalized medicine products. The Company has established strategic alliances with Bayer, Eli Lilly, Hitachi, Novartis, Pharmacia, Roche, Schering AG and Schering-Plough.

Note to Editors: This and other recent releases are available on Myriad`s Web site at www.myriad.com.

The discussion in this news release includes forward-looking statements that are subject to certain risks and uncertainties, including statements regarding the effect of the combination of yeast two-hybrid and mass spectrometry technologies, the value for drug developers created by ProSpec, the use of ProSpec by the Company and its pharmaceutical partners in drug discovery programs, the effect of proteomics on the field of medicine, the number of drug targets that proteomics will produce over the next few years, the effectiveness of proteomics-derived medicines and their impact on side effects, the impact of proteomics-derived medicines on the success and length of clinical trials, the impact of ProNet in delivering disease pathways and continued protein function information, the impact of ProSpec and ProNet on the knowledge proteomics delivers, and the Company`s use of ProSpec in strategic alliances. Such statements are based on management`s current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements, including, but not limited to, intense competition related to the discovery of disease-related genes; uncertainties as to the extent of future government regulation of the Company`s business, uncertainties as to whether the Company and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutics based on the discovery of disease-related genes and proteins; uncertainties as to the Company`s ability to develop therapeutic lead compounds, which is a new business area for the Company; the risk that markets will not exist for therapeutic lead compounds that the Company develops or if such markets exist, that the Company will not be able to sell compounds, which it develops, at acceptable prices.

SOURCE Myriad Genetics, Inc.




Related Tickers:
MYGN 107 1/2 2 1/16
NVS 37 13/16 - 13/64


Myriad Genetics Introduces ProSpec(TM) - New Generation Mass Spectrometry/Proteomics Technology- ProSpec and ProNet Coupled to Enhance Myriad Drug Discovery Programs -
SALT LAKE CITY, Oct 17, 2000 /PRNewswire via COMTEX/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has introduced ProSpec(TM), a powerful new drug target identification and validation technology. This new proteomics technology complements the disease pathway discovery capability of Myriad`s ProNet(TM) technologies with the use of mass spectrometry to identify protein complexes. Complexes of interacting proteins are required for virtually all biological processes in the cell. The unique combination of Myriad`s ProNet version of yeast two-hybrid and mass spectrometry technologies creates an unparalleled tool for drug discovery and development.

As a leader in proteomics, Myriad introduced ProSpec to better understand how proteins function in human disease. ProSpec complements Myriad`s ProNet technology by enabling detection of extracellular protein interactions and protein complexes containing proteins that require modification for the interactions to occur. In addition, ProSpec uses the mass spectrometer to deliver structural information about three dimensional protein complexes. This information, coupled with ProNet data, may lead to considerable acceleration in the discovery of novel drug targets for both treatment and prevention of human disease.

"ProSpec is a giant leap forward in creating real value for drug developers out of information from the human genome," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "Myriad`s internal drug discovery programs and those of our pharmaceutical partners will both employ high-throughput protein interaction technology and mass spectrometry for three dimensional protein complexes to identify important disease pathways and promising drug targets in those pathways."

No other proteomics company, to the Company`s knowledge, has introduced an integrated pathway discovery technology that incorporates both yeast two-hybrid and mass spectrometry tools. The ProSpec technology is particularly amenable to large-scale protein identification projects.

Only 5% of the human genome has an obviously important function. This 5% of the DNA is the portion that codes for proteins. First generation proteomics technologies provided basic protein information such as the sequence of the protein and the relative quantity of the proteins in disease tissues. Protein interaction technologies, such as Myriad`s ProNet, are a major advancement in that they provide an understanding of the complete disease pathway and the cellular processes that result in disease. ProNet identifies key regulators and potential drug targets in the disease pathway. These disease pathway proteins form three-dimensional complexes in which portions of proteins may be buried in the complex and unavailable for binding. ProSpec builds upon pathway identification by identifying the entire set of proteins that form multiprotein complexes. The knowledge of these proteins and the complexes they form is highly valuable for determining the druggability of a protein. Druggable targets are those that can be addressed with vaccines, small molecules, therapeutic antibodies or protein therapy approaches.

ProSpec not only identifies the set of proteins that make up a multiprotein complex, it is also effective in identifying protein interactions that require post-translational modification. For example, certain proteins require methylation or phosphorylation by enzymes before they can perform their functional role in the cell. These interactions can be detected with ProSpec although they are often invisible to other detection methods. ProSpec is highly sensitive and is amenable to very high throughput. One of the most appealing characteristics of the ProSpec technology is that it identifies protein interactions as they occur in vivo, in the natural state inside the human cell.

About Proteomics

Myriad firmly believes that proteomics will revolutionize medicine. Prior to the genomic age, all drug discovery efforts worldwide, at all pharmaceutical companies combined, developed drugs targeting only approximately 500 different proteins. These 500 drug targets are mostly from the same few overused classes of proteins. These targets are insufficient to maintain the industry`s rate of growth while building the entire future of medicine. Despite spending billions of dollars annually screening hundreds of thousands of compounds against these targets, only a very small number of new drugs are introduced commercially. To add to the difficulty, these compounds only treat the symptoms of disease, leaving the root cause of the problem unaffected.

In contrast, it is commonly believed that proteomics will produce thousands of new drug targets over the next several years. The sequencing of the human genome has accelerated the drug target discovery process to the point that the challenge is identifying the most promising, druggable targets from among the large number of possibilities. A good strong druggable target requires knowledge of the disease pathway, protein function, structure and availability.

Proteomics answers the challenge. Proteins interact with one another and form complexes to carry out essentially all human biological processes. To discover the chain of events that result in a disease state, drug developers must identify the disease pathway and the proteins involved in that pathway. Proteomics delivers this information precisely and efficiently. Proteomics- derived medicines, based on the cause of disease, not the symptoms, should be more effective with reduced side effects. These new safer drugs are also more likely to produce successful clinical trials in a reduced timeframe.

Myriad`s ProNet technology has already delivered disease pathways and protein function information and will continue to do for the Company`s global proteomics partners. The even more potent and rapid combination of ProSpec and ProNet will further the knowledge proteomics delivers by adding structure and availability, enhancing the odds of making the optimum choice of drug target for faster development of better, safer and more effective medicines.

Myriad, furthering its leadership position in proteomics, will also use ProSpec in strategic alliances to assist major pharmaceutical companies in the identification of the most promising set of druggable targets to fill their pipelines for the next generation of medicines. Proteomic technology advances such as these enable the projected industry growth from $300 billion today to the third-party projected $3 trillion by 2020.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel therapeutic products derived from its proprietary genomic and proteomic technologies. The Company has established two wholly owned subsidiaries. Myriad Pharmaceuticals, Inc. develops and intends to market therapeutic compounds, and Myriad Genetic Laboratories, Inc. develops and markets proprietary predictive medicine and personalized medicine products. The Company has established strategic alliances with Bayer, Eli Lilly, Hitachi, Novartis, Pharmacia, Roche, Schering AG and Schering-Plough.

Note to Editors: This and other recent releases are available on Myriad`s Web site at www.myriad.com.

The discussion in this news release includes forward-looking statements that are subject to certain risks and uncertainties, including statements regarding the effect of the combination of yeast two-hybrid and mass spectrometry technologies, the value for drug developers created by ProSpec, the use of ProSpec by the Company and its pharmaceutical partners in drug discovery programs, the effect of proteomics on the field of medicine, the number of drug targets that proteomics will produce over the next few years, the effectiveness of proteomics-derived medicines and their impact on side effects, the impact of proteomics-derived medicines on the success and length of clinical trials, the impact of ProNet in delivering disease pathways and continued protein function information, the impact of ProSpec and ProNet on the knowledge proteomics delivers, and the Company`s use of ProSpec in strategic alliances. Such statements are based on management`s current expectations that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements, including, but not limited to, intense competition related to the discovery of disease-related genes; uncertainties as to the extent of future government regulation of the Company`s business, uncertainties as to whether the Company and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutics based on the discovery of disease-related genes and proteins; uncertainties as to the Company`s ability to develop therapeutic lead compounds, which is a new business area for the Company; the risk that markets will not exist for therapeutic lead compounds that the Company develops or if such markets exist, that the Company will not be able to sell compounds, which it develops, at acceptable prices.

SOURCE Myriad Genetics, Inc.


CONTACT: William A. Hockett, Director of Corporate Communications of
Myriad Genetics, Inc., 801-584-3600, [e-mail]

URL: http://www.myriad.com
http://www.prnewswire.com


macht euch mal an die übersetzung...!!!!
mfg
WMFM

[mahatma]

[mahatma]

heute im Aktionär:
Myriad Genetics spekulativ kaufen !!!!!!!!!
warum ,weshalb , wieso?????

hier die news Die Analysten des Börsenmagazins “Der Aktionär” berichten, daß
US-Unternehmen Myriad Genetics (WKN 897518), welches eigentlich als
Dienstleister für die Pharmaindustrie fungiere, in Zukunft selbst die
Entwicklung in die Hand nehmen will.

Derzeit forsche das Unternehmen an 46 Wirkstoffzielen, von denen man
bereits 10 an strategische Partner lizenziert habe. Erst vor kurzem habe
Myriad Studien veröffentlicht, die die Entdeckung des Proteins mit dem
Namen HPC2 beschreiben. HPC2 werde mit dem erblich bedingten
Prostata-Krebs in Verbindung gebracht and stehe unter dem Verdacht, der
Auslöser für einige andere Krebsarten zu sein.

dies stelle natürlich einen besonders großen Fortschritt im Kampf gegen
diese Krankheit dar. Die Analysten empfehlen daher dem spekulativen
Anleger, sich die Aktien ins Portfolio zu legen.

tolllllllllllllll, weiter so ffffffffffffffööööööööööööötttttttttssssssssssccccccccccchhhhhhhhhhhhhh iiiiiiiiiiiiiiiiiiiii

gruß maha

[Nelson99]

Ist Myriad nicht gerade dabei, ein Doppeltop auszubilden ?

Nelson

[Rantangoose]

Denke nicht .......sollte nach "verdienter" Verschnaufpause weiter Bergauf gehen

[mahatma]

Gregory Critchfield, President of Myriad Genetics geht heute wieder rannnnnnnnnnnnnn !!!!
neues Glück neue Partner;
da ganze unter http://quote.fool.com/News/symbolnews.asp?symbols=MYGN&currt…

gruß maha

[mahatma]

wir gehen wieder (weiter) Richtung Norden
MYGN ist einfach eine super Chance , auch für die noch nicht investierten !!!!!!!!

also rein in diese geile Aktieeeeeeeeeeeeeeeee

gruß maha

[Zocker-Uwe]

Bin nicht in Myriad investiert, halte sie aber für einen
der absolut aussichtsreichsten Biotecs ! Nach dem Verdoppler
in 4 Wochen tu ich mich jetzt aber schwer noch einzusteigen.
Vielleicht kriege ich sie nochmal unter 100 €. Was meint ihr ?
Bei einer Marktkapitalisierung von ca 2,6 Mrd € sind die zwar nicht
billig, aber in Anbetracht der Zukunftsaussichten immer noch ein
100% Kandidat auf 12 Monate, oder gar mehr...

[mahatma]

ohne Kommentar:

so 3 Wochen lang !!!!!! und ich könnte die Löffel weglegen

aber im Ernst: Myriad ist einfach ein TOP-Wert
grüße an alle]
maha

[mahatma]

ach so,
hier noch die guten news: KAUF- EMPFEHLUNG von CIBC WORLD MARKETS !!!
s.a.http://www2.marketwatch.com/quotes/quotes.asp?source=htx/htt…

maha

[Börsenguru2001]

So, jetzt nehmen wir in den nächsten Tagen das ATH in Angriff und wir werden siegen!!!!!!!!!!!!!!!!!

[vita01]

Myriad Genetics mit starker Umsatzsteigerung

Das Biotechnologieunternehmen Myriad Genetics (Nasdaq: MYGN) konnte im vergangenen Quartal den Umsatz um 58 Prozent steigern und die Verluste um 25 Prozent einschränken. Die Analystenberechnungen wurden damit geschlagen.

Die Umsätze vermehrten sich von 6,9 Mio. auf 10,8 Mio. Dollar. Größere Umsätze aus dem Forschungsbetrieb und starke Zuwächse (+89 Prozent) im Bereich der vorbeugenden Medizin waren dafür ausschlaggebend.

Der Nettoverlust belief sich auf 2,1 Mio. Dollar oder 9 Cent je Aktie, nachdem im Vorjahr noch ein Minus von 12 Cent je Aktie verbucht werden musste. Die Analystenschätzungen siedelten sich im Bereich von 11 Cent je Aktie an, konnten also deutlich übertroffen werden.

Erst am Dienstag wurde die Beschaffung neuer Investitionsgelder verkündet ..weiter. Ferner wurde Myriad Genetics vom Analystenhaus Bear Stearns auf „Buy“ und von JP Morgan auf „Strong Buy“ eingestuft.

Auf den Kurs hat die Nachricht heute keinen Einfluss. Aktuell ist ein leichtes Minus von 0,2 Prozent zu verzeichnen.

19:02 2.11 Stefan Ochsenkühn

[mahatma]

das ist die RUHE VOR DEM STURM
Cool und ruhig warten wir mal ab , was da kommt ( nicht nervös werden wegen heute) !!!

grüße alle fans maha

[Börsenguru2001]

Ist das geil, ich bin mit 76Euro eingestiegen und jetzt habe ich fast 100% Gewinn und es ist kein Ende in Sicht!!!!!!!!!
Morgen gehts nach Norden! (zur Kursk, nur wir gehen nicht unter)

[mahatma]

Fakten, Fakten:
der Tag danach ( bedarf keiner Worte)



gruß maha

[Shareholdersnightmare]

Nochmal zu den Gewinnmargen von Biotechunternehmen:

Damit Ihr einmal einen Eindruck bekommt, was Biotechunternehmen ungefähr für Gewinne aus Ihren Umsätzen erzielen können, wollte ich Euch einfach mal posten, daß z.B. Amgen trotz sehr hoher Ausgaben eine Nettogewinnmarge von ca. 35% haben. Obwohl ich dort nicht unbedingt investieren will, bzw. werde, ist das doch sehr ansehlich.

Einfach nur mal so ein Anhaltspunkt, um Euer persönliches Kursziel für Synsorb vielleicht noch zu konkretisieren.


Stay long and strong...

[Shareholdersnightmare]

Oooops! Sorry!

Falscher Thread (aus Versehen) - aber kann ja nicht schaden sich mal etwas neues anzuschauen... Von MYGN bin ich übrigens auch sehr angetan - momentan stört mich die etwas überkaufte Charttechnik nur etwas...


Stay long...

[mahatma]

toll wie MYGN heute wieder abgeht
einfach eine TOP - Aktie !!!!!!!!!!!!!!

gruß maha

[mahatma]

Das sind sieieieieieieieieieie, die netten (strong buy)Jungs:
Covering Brokers
Bear Stearns and Company, Incorporated
CIBC World Markets
Dain Rauscher Wessels, Incorporated
Josephthal and Company, Incorporated
Merrill Lynch and Company
Morgan Stanley,Dean Witter and Company
Prudential Securities, Incorporated
Thomas Weisel Partners

ihnen allen wünsche ich ewiges Leben !!!!!!!!

Myriad der TOP - Wert 2000 und auch 2001 , heute wieder mächtig im Plus

maha

[TheFrog]

Hej Leute schaut euch mal www.brokerstalk.de.vu an

[mahatma]

heute schon wieder so ein schöner Waaahhhhnnnsiiiiiiiiiiiiiiiiinnnnnnnnnnnn


mir zerreisst es das Herz (vor Freude natürlich !!!!)

MYGN ist einfach eine läufige geile brünstige Aktie,
man kann nicht genug davon bekommen

MYGN ggogogogogogogogogogogogogogogogog



maha

[cdr74]

ohne Kommentar
( BW)(CA-IDEC-PHARMACEUTICALS)(IDPH) Acceptance of Biologics
License Application for Zevalin Radioimmunotherapy Announced by IDEC
Pharmaceuticals


Business Editors & Health/Medical Writers
BIOWIRE2K

SAN DIEGO--(BW HealthWire)--Jan. 2, 2001--IDEC Pharmaceuticals Corporation
(Nasdaq:IDPH) today announced that the Biologics License Application (BLA) for
ZEVALIN(TM)(Ibritumomab Tiuxetan) has been accepted for filing by the U.S. Food and Drug
Administration.
The action means that the FDA has determined that the submission contains sufficient information
for the Agency to perform a meaningful review for marketing authorization.
The FDA has also approved IDEC`s request for priority review of the ZEVALIN BLA, meaning
that the Agency`s review of the filing should be completed within six months of submission, although
final approval, if at all, may require additional time. The company submitted the BLA to the FDA on
November 1, 2000 for marketing approval. The proposed indication for ZEVALIN is for the
treatment of low grade, follicular, CD20-positive transformed, relapsed or refractory, B-cell
non-Hodgkin`s lymphoma (NHL) and Rituximab-refractory follicular NHL, which are cancers of the
lymphatic system. If approved, ZEVALIN would be the first or one of the first radioimmunotherapies
available for commercial use in the United States.
"We are very pleased that the ZEVALIN BLA has been accepted by the FDA," said William H.
Rastetter, chairman, chief executive officer and president of IDEC Pharmaceuticals. "This effort
concludes years of hard work on the part of almost every IDEC employee. In the months ahead, we
will continue to work closely with the FDA to facilitate the approval process."
IDEC Pharmaceuticals focuses on the commercialization and development of targeted therapies for
the treatment of cancer and autoimmune diseases. IDEC`s antibody products act chiefly through
immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in
the patient`s blood or lymphatic systems. For a menu of IDEC`s current news releases and quarterly
reports or to retrieve a specific release, call [phone]. On the Internet check the News Center
at IDEC`s website: http://www.idecpharm.com.

The statements made in this press release contain certain forward-looking statements that involve a
number of risks and uncertainties. Actual events or results may differ from IDEC`s expectations. For
example, the timing, success and cost of preclinical research and clinical studies, the timing,
acceptability and review periods for regulatory filings, the timing of and ability to obtain regulatory
approval of products, such as ZEVALIN, the achievement of future product sales, the level of
manufacturing performance and the risk factors listed from time to time in IDEC`s SEC filings including
but not limited to its S-3 filed November 16, 2000, its Annual Report on Form 10-K for the year
ended December 31, 1999 and Form 10-Q for the quarter ended September 30, 2000, may affect
the actual results achieved by IDEC. These forward-looking statements represent the company`s
judgment as of the date of this release. The company disclaims, however, any intent or obligation to
update these forward-looking statements.

IDEC Pharmaceuticals and Rituxan are registered U.S. trademarks of the company. ZEVALIN is a
trademark of the company. The company`s headquarters is located at 3030 Callan Road, San Diego,
CA 92121.

IDEC Pharmaceuticals` press releases are available at no charge through Business Wire`s News on
Demand Plus. For a menu of IDEC`s current press releases and quarterly reports or to retrieve a
specific release, call 888/329-2309. On the Internet, check the News Center at IDEC`s website
http//www.idecpharm.com.

--30--jv/sd* js/sd ts/sd

CONTACT: IDEC Pharmaceuticals, San Diego
Connie Matsui, Senior Vice President
Planning & Resource Development
858/431-8656

KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL
cdr74

[money_max]

Und trotzdem gings nachbörslich bis auf $170 runter! Das verstehe wer will!




Shares of Idec Pharmaceuticals slipped $11.81 to $177.75, even though the company had an apparently encouraging announcement Tuesday. Idec Pharmaceuticals said the U.S. Food and Drug Administration had accepted the company`s application for marketing authorization for a cancer drug, Zevalin. While the acceptance doesn`t guarantee an FDA approval, it does bring Idec a step closer toward getting the agency`s OK to market the drug.

But even if Zevalin gets the nod from the FDA, the drug won`t have as big a market as Idec`s other cancer treatment, Rituxan, said Bennett Weintraub, a vice president with Btech Consulting. Zevalin is expected to be administered only once per patient, limiting its potential market, said Weintraub, whose Beverly Hills, Calif.-based firm advises biotech investors.

Still, Weintraub said he is bullish on the prospects of Idec partly because of the Rituxan drug, which is used in treating non-Hodgkin`s lymphoma.

"Rituxan by itself is quite valuable," Weintraub said.


By Ted Griffith, CBS.MarketWatch.com
Last Update: 4:50 PM ET Jan 2, 2001

[mahatma]

lieber ein schöööner Wahnsinn als dieser Niedergang !!!!
deshalb hoffe ich auf diese NEWS:
http://www2.marketwatch.com/quotes/quotes.asp?source=htx/htt…

ab sofort bitte keine zittrigen Hände mehr !!!!!



gruß maha

[cdr74]

kleiner Joke am Rande
schaut mal auf Freerealtime.com den Ask für IDPH an, da hauts euch aus den Latschen
das wäre schon was, wird wohl ein durchgeknallter Makler sein
ask 415 11/16 14.22 Uhr (MEZ)
fool on
cdr74

[cdr74]

schade leider zu spät jetzt ist er weg, und liegt bei 187
cdr74

[money_max]

IDEC Pharmaceuticals Begins Phase II Study in Immune Thrombocytopenic Purpura (ITP) With Its Humanized Antibody, IDEC-131

SAN DIEGO, Jan 4, 2001

IDEC today announced that it has initiated a Phase II clinical trial with its investigational agent, IDEC-131, a humanized anti-CD154 (anti-CD40L) monoclonal antibody. The multiple-center, multiple-dose study will evaluate the potential clinical activity and safety of this investigational agent in patients with chronic, refractory immune thrombocytopenic purpura (ITP), a blood disorder characterized by low platelet counts which can pose a significant risk of life-threatening bleeding.

"We believe that IDEC-131 has potential benefit as a therapeutic agent for diseases such as ITP that are characterized by the production of autoantibodies," said Mark Totoritis, M.D., senior director, autoimmmune and inflammatory diseases. "In fact, preliminary evidence of improvement in platelet counts has been observed in an ongoing clinical investigation of IDEC-131 in a small number of ITP patients at Weill Medical College of Cornell University."

IDEC-131 targets a key pathway in the immune system -- the CD154-CD40 pathway -- that involves collaboration between T cells and B cells, as well as other antigen-presenting cells. Therefore, this antibody therapeutic may have application in diseases that are caused by overactive T cells and in those that are characterized by excessive autoantibody production by B cells.

IDEC-131 is based on technology that IDEC licensed from Dartmouth University, where researchers have demonstrated the beneficial effects of the anti-CD154 antibody in animal models of autoimmunity.

Eisai Company, Ltd. has licensed the commercial rights of IDEC-131 in Europe and Asia. IDEC retains exclusive rights outside of Europe and Asia.

IDEC Pharmaceuticals focuses on the commercialization and development of targeted therapies for the treatment of cancer and autoimmune diseases. IDEC`s antibody products act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient`s blood or lymphatic systems.

[moneyconny]

Hallo,
warum höre ich nichts mehr von Myriad Genetics. Gibt es da was Neues, weis jemand was? Soll ich halten, kaufen, verkaufen...?Ich weis, daß es ein Super-Wert ist, habe aber langsam keine Nerven mehr für die Bio-Tech`s.

[mahatma]

schau dich mal um bei:
http://www.smartmoney.com/eqsnaps/index.cfm?story=competitio…

dort findest du alles über unseren TOP-Wert !!!!
(Consensus Analyst Recommendation = natürlich STRONG BUY
also schau mal vorbei und du wirst wieder ruhig schlafen können.

gruß maha

[moneyconny]

hallo maha,
danke für deine info. vielleicht reicht die ja, um wenigstens die kommende nacht durchzuschlafen. werde mir morgen mal die reaktionen auf die nachricht ansehen und dann entscheiden.
mc

[RudiDutschke]

Guten Morgen, auch im Backfire newsletter unter den Empfehlungen der letzten drei Tage ein buy und ein strong buy von UBS für MYGN. Hoffe ebenfalls auf bessere Nächte.